Stability of magistral phage preparations before therapeutic application in patients with chronic rhinosinusitis, sepsis, pulmonary, and musculoskeletal infections

Microbiol Spectr. 2023 Dec 12;11(6):e0290723. doi: 10.1128/spectrum.02907-23. Epub 2023 Oct 11.

Abstract

As antimicrobial resistance becomes more prevalent, the application of (bacterio)phage therapy as an alternative treatment for difficult-to-treat infections is (re)gaining popularity. Over the past decade, numerous promising case reports and series have been published demonstrating the therapeutic potential of phage therapy. However, important questions remain regarding the optimal treatment protocol and, unlike for medicinal products, there are currently no predefined quality standards for the stability of phage preparations. Phage titers can be influenced by several factors which could lead to reduced titers after preparation and storage and, ultimately, subtherapeutic applications. Determining the stability of different phages in different recipients according to the route of administration is therefore one of the first important steps in establishing a standardized protocol for phage therapy.

Keywords: bacteriophages; formulation; phage therapy; phages; stability.

MeSH terms

  • Bacterial Infections* / therapy
  • Bacteriophages*
  • Humans
  • Phage Therapy* / methods
  • Rhinosinusitis*
  • Sepsis*